What question did this study set out to answer?

To explore the role of thyroglobulin and thyroglobulin antibodies in monitoring differentiated thyroid cancer and address interpretation challenges.

May 1, 2026Open Access

Thyroglobulin and Thyroglobulin Antibodies in Differentiated Thyroid Cancer: Interpretation, Challenges and Future Perspectives

MLM.H. LinksUniversity Medical Center Groningen TLTP LinksUniversity Medical Center Groningen WZW T ZandeeUniversity Medical Center Groningen

Key Points

To explore the role of thyroglobulin and thyroglobulin antibodies in monitoring differentiated thyroid cancer and address interpretation challenges.
Review of thyroglobulin and thyroglobulin antibody measurement methodologies and their clinical implications.
Discussion of emerging technologies like liquid biopsies and proteomics for thyroid cancer diagnosis and monitoring.
Tg is crucial for monitoring treatment response and disease recurrence in DTC patients, but its measurement can be complicated by TgAbs.
High levels of TgAbs interfere with Tg measurements, potentially leading to false-negative results, highlighting the need for concurrent TgAb testing.
Novel methods like proteomics and liquid biopsy are emerging for non-invasive disease monitoring, although their efficacy in DTC is still being evaluated.

Abstract

Thyroglobulin (Tg) is a thyroid-specific protein playing a key role in thyroid hormone production. For patients with differentiated thyroid carcinoma (DTC), Tg is the main biomarker during follow-up determining treatment response and risk of disease recurrence. Accurate Tg measurement is complicated by assay-specific performance and interference, most notably thyroglobulin autoantibodies (TgAbs). High-sensitivity Tg assays can detect very low Tg levels, eliminating the need for TSH-stimulated Tg-measurements. Because of potential TgAb interference in Tg assays, TgAb measurement must always accompany Tg analysis. TgAbs are present in a minority of healthy individuals, but in up to one third of patients with DTC. While low-level TgAbs are often clinically irrelevant, higher titers interfere with Tg immunoassays, possibly causing false-negative Tg results. Importantly, TgAb trends themselves provide prognostic information: declining concentrations support remission, whereas rising titers may indicate recurrence, offering a potential useful surrogate marker when Tg is unreliable. Alternative and complementary laboratory strategies are emerging. Novel proteomic approaches may allow isoform-specific Tg detection, potentially distinguishing tumour-derived Tg from normal Tg. In parallel, liquid biopsy technologies, particularly cell-free DNA, circulating tumour DNA and microRNA assays, are being explored for non-invasive detection of minimal residual disease, though their role in DTC remains to be defined. In summary, Tg and TgAbs remain the mainstay of laboratory monitoring in DTC. Their interpretation demands awareness of assay limitations, appropriate cut-offs, and the clinical context. Future integration of advanced proteomic and genomic biomarkers holds promise for more specific, individualized surveillance strategies in thyroid cancer.

Ask AI

Helpful

Bookmark

View Full Paper